Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-1558 Phase 1 Safety and PK Study in Healthy Volunteers
NCT05364840Phase 1Completed
- Sponsor
- Sorrento Therapeutics
- Start
- Jun 2022
- Primary completion
- Oct 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olgotrelvir in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Sorrento Therapeutics. Primary endpoints: Incidence of adverse events at Day 42 and Cardiac function assessment at Day 42. Started Jun 2022; status: completed.
02
Drugs
olgotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05364840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364840.